🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

One Year Mortality and Morbidity With Hyperglycemia Among Acute Cerebrovascular Accident Patients in Emergency Department: A Cohort Study

Recruitingn/aAges 18 Years - anyAllInstitute of medicine, Maharagjung medical campus
NCT06560983 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The "One Year Mortality and Morbidity Outcome with Hyperglycemia among Acute Cerebrovascular Accident Patients in Emergency Department" is an extensive prospective cohort study designed to look into how hyperglycemia affects the short- and long-term outcomes of patients who present to the emergency room with acute cerebrovascular accidents (CVAs). Worldwide, cerebrovascular accidents are a major source of both death and morbidity. Research on the long-term consequences of hyperglycemia and its association with worse outcomes during the acute period of stroke is still underway. This study aims to close this information gap by investigating the relationship between the rates of immediate short- and one-year mortality rates and morbidity and hyperglycemia at the time of CVA presentation. The research design adopts a prospective cohort approach, aligning with established guidelines to ensure

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Individuals exhibiting BEFAST-positive symptoms - meeting at least one of the criteria within 24 hours of symptom onset. * Confirmation of acute stroke through CT imaging. * Participants aged over 40 years. Exclusion Criteria: * Patients presenting with hypoglycemia * Transient Ischemic Attack (TIA). * Subdural hematoma cases. * Subarachnoid hemorrhage cases. * Diabetic Ketoacidosis. * Conditions mimicking stroke symptoms (e.g., sepsis, metabolic derangement, space-occupying lesions, hepatic encephalopathy). * History of bedridden patients. * Acute-on-chronic stroke cases. * Patients requiring assistance in daily activities. * History of trauma preceding the stroke.
💊

What it tests

  • The investigators are planning to do a observational cohort study, hence won't be doing any intervention.
📍

Where

2 sites
Bibek Rajbhandari
Kathmandu, Nepal
Bibek Rajbhandari
Kathmandu, Nepal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy